Esperion Therapeutics Inc
$ 3.79
0.26%
04 Dec - close price
- Market Cap 898,492,000 USD
- Current Price $ 3.79
- High / Low $ 3.91 / 3.76
- Stock P/E N/A
- Book Value -2.20
- EPS -0.54
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -2.61 %
- 52 Week High 4.03
- 52 Week Low 0.69
About
Esperion Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, dedicated to developing innovative therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). The company's primary focus is on transforming the treatment landscape for cardiovascular disease through its novel lipid-lowering agents. With a robust pipeline and a commitment to patient-centered solutions, Esperion is well-positioned to significantly impact the management of dyslipidemia and improve patient outcomes in a critical area of cardiovascular health.
Analyst Target Price
$6.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-13 | 2025-05-05 | 2025-02-25 | 2024-11-05 | 2024-08-12 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-01 | 2023-05-09 | 2023-02-21 |
| Reported EPS | -0.16 | -0.06 | -0.2063 | -0.1013 | -0.15 | -0.33 | 0.34 | -0.5 | -0.37 | -0.46 | -0.79 | -0.76 |
| Estimated EPS | 0.02 | -0.14 | -0.15 | -0.1575 | -0.18 | -0.18 | 0.05 | -0.48 | -0.43 | -0.61 | -0.65 | -0.84 |
| Surprise | -0.18 | 0.08 | -0.0563 | 0.0562 | 0.03 | -0.15 | 0.29 | -0.02 | 0.06 | 0.15 | -0.14 | 0.08 |
| Surprise Percentage | -900% | 57.1429% | -37.5333% | 35.6825% | 16.6667% | -83.3333% | 580% | -4.1667% | 13.9535% | 24.5902% | -21.5385% | 9.5238% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.2937 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ESPR
2025-10-17 17:15:45
Esperion Therapeutics is recommitting to research for Primary Sclerosing Cholangitis (PSC), a disease currently without approved treatments that affects thousands in the U.S. and Europe. The company aims to develop new therapies for this challenging condition, emphasizing scientific innovation to address unmet medical needs and improve patient lives. This initiative highlights Esperion's focus on groundbreaking solutions for PSC.
2025-10-17 17:02:31
Esperion Therapeutics (ESPR) is expanding its pipeline beyond cardiovascular diseases with ESP-2001, a preclinical candidate for Primary Sclerosing Cholangitis (PSC), a rare autoimmune liver disease. Shares of Esperion rose 5.2% following the announcement. The company plans to initiate clinical studies for ESP-2001 in 2026, aiming to tap into a potential blockbuster market and diversify its revenue streams.
2025-10-17 12:28:46
Cantor Fitzgerald has reiterated its Overweight rating on Esperion stock, maintaining a $9 price target. The article title suggests an analyst rating and price target for Esperion.
2025-10-16 21:31:58
Esperion has nominated ESP-2001 as a preclinical development candidate for Primary Sclerosing Cholangitis (PSC), a devastating liver disease with no approved treatments. ESP-2001 is a highly-specific allosteric ATP citrate lyase (ACLY) inhibitor designed to target liver and bile duct injury, inflammation, and fibrosis associated with PSC. The company plans to file an IND with the FDA in 2026 to initiate first-in-human clinical studies, projecting a potential multi-billion dollar market opportunity.
2025-10-16 12:15:07
Esperion has nominated ESP-2001, a highly-specific allosteric ATP citrate lyase (ACLY) inhibitor, as a preclinical development candidate for Primary Sclerosing Cholangitis (PSC). This marks an expansion of Esperion's therapeutic focus beyond cardiovascular disease, addressing a condition with no approved treatments. The company plans to begin IND-enabling studies with a goal to file an IND with the FDA to initiate first-in-human clinical studies in 2026, leveraging its expertise in ACLY therapy and a partnership with Evotec.
2025-10-16 12:00:00
Esperion (NASDAQ: ESPR) has nominated ESP-2001 as its preclinical development candidate for Primary Sclerosing Cholangitis (PSC), targeting an IND filing with the FDA in 2026. Preclinical models showed positive results in reducing markers of liver and bile duct injury, inflammation, and fibrosis. The company retains exclusive global rights and estimates a potential annual market exceeding $1 billion, with ESP-2001 possibly qualifying for Orphan Drug, Fast Track, and PRIME designations.
